FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1021-1027 September 30, 1993 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Parkinson's disease (idiopathic parkinsonism or paralysis agitans) is characterized clinically by progressive tremor, bradykinesia, and rigidity and pathologically by degeneration of the dopaminergic nigrostriatal pathway, decreases in the striatal concentration of dopamine, and the presence of laminated inclusions (Lewy bodies) in neurons of the substantia nigra. The cause (or causes) of Parkinson's disease is not known, and the pathophysiology is poorly understood. However, there is a considerable body of knowledge concerning the disturbances of synaptic function. Degeneration of the nigrostriatal pathway leads to the depletion of the neurotransmitter dopamine. Since dopamine does not readily cross the blood-brain barrier, the major . . . [Full Text of this Article]

Antiparkinsonian Drugs

Symptomatic Therapy

            Anticholinergic Agents and Amantadine

            Levodopa

            Synthetic Dopamine Agonists

Protective Therapy

Management of Different Stages of Disease

Newly Diagnosed Parkinson's Disease

Severe Parkinson's Disease

Management of Adverse Reactions to Therapy

Implications of Current Research

Surgery

Unconventional Routes of Administration

New Drugs

Conclusions

Source Information

From the Neurodegenerative Disorders Center, Division of Neurology, Department of Medicine, University of British Columbia, University Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada, where reprint requests should be addressed to Dr. Calne.

References

Related Letters:

Treatment of Parkinson's Disease
Grieger T. A., Cozza K., Armstrong S., Calne D.B.
Extract | Full Text  
N Engl J Med 1994; 330:643-644, Mar 3, 1994. Correspondence

This article has been cited by other articles:

• Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]  
• Fontenla, M., Gould, D. (2003). Young people with Parkinson's disease: Report of a pilot study to identify the research issues and approaches to data collection. Journal of Research in Nursing 8: 213-226 [Abstract]  
• Jarman, B., Hurwitz, B., Cook, A., Bajekal, M., Lee, A. (2002). Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial. BMJ 324: 1072-1072 [Abstract] [Full Text]  
• Hubble, J. P. (2002). Long-term studies of dopamine agonists. Neurology 58: S42-50 [Abstract] [Full Text]  
• Koller, W. C. (2002). Treatment of early Parkinson's disease. Neurology 58: S79-86 [Abstract] [Full Text]  
• Ueda, M, Hamamoto, M, Nagayama, H, Okubo, S, Amemiya, S, Katayama, Y (2001). Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J. Neurol. Neurosurg. Psychiatry 71: 111-113 [Abstract] [Full Text]  
• Olanow, C. W., Watts, R. L., Koller, W. C. (2001). An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment. Neurology 56: S1-S88 [Full Text]  
• (2001). A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56: 455-462 [Abstract] [Full Text]  
• Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., Chase, T. N. (2000). AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54: 1589-1595 [Abstract] [Full Text]  
• Bernard, V., Levey, A. I., Bloch, B. (1999). Regulation of the Subcellular Distribution of m4 Muscarinic Acetylcholine Receptors in Striatal Neurons In Vivo by the Cholinergic Environment: Evidence for Regulation of Cell Surface Receptors by Endogenous and Exogenous Stimulation. J. Neurosci. 19: 10237-10249 [Abstract] [Full Text]  
• Marek, K. (1999). Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging. Neuroscientist 5: 333-340 [Abstract]  
• Ueda, M., Hamamoto, M., Nagayama, H., Otsubo, K., Nito, C., Miyazaki, T., Terashi, A., Katayama, Y. (1999). Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 52: 777-777 [Abstract] [Full Text]  
• Bernard, V., Laribi, O., Levey, A. I., Bloch, B. (1998). Subcellular Redistribution of m2 Muscarinic Acetylcholine Receptors in Striatal Interneurons In Vivo after Acute Cholinergic Stimulation. J. Neurosci. 18: 10207-10218 [Abstract] [Full Text]  
• Shoulson, I. (1998). Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs. Science 282: 1072-1074 [Abstract] [Full Text]  
• Sethi, K. D., O'Brien, C. F., Hammerstad, J. P., Adler, C. H., Davis, T. L., Taylor, R. L., Sanchez-Ramos, J., Bertoni, J. M., Hauser, R. A., for the Ropinirole Study Group, (1998). Ropinirole for the Treatment of Early Parkinson Disease: A 12-Month Experience. Arch Neurol 55: 1211-1216 [Abstract] [Full Text]  
• Yoshimura, N., Mizuta, E., Yoshida, O., Kuno, S. (1998). Therapeutic Effects of Dopamine D1/D2 Receptor Agonists on Detrusor Hyperreflexia in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian Cynomolgus Monkeys. J. Pharmacol. Exp. Ther. 286: 228-233 [Abstract] [Full Text]  
• Donnellan, C A, Fook, L, McDonald, P, Playfer, J R (1997). Lesson of the week: Oxybutynin and cognitive dysfunction. BMJ 315: 1363-1364 [Full Text]  
• Nihart, M. A. (1997). Atypical Antipsychotics and the Pharmacology of Olanzapine. J Am Psychiatr Nurses Assoc 3: S2-S7 [Abstract]  
• Grieger, T. A., Cozza, K., Armstrong, S., Calne, D.B. (1994). Treatment of Parkinson's Disease. NEJM 330: 643-644 [Full Text]